ES2526671T3 - Compuestos de benzotriazoldiazepina inhibidores de bromodominios - Google Patents
Compuestos de benzotriazoldiazepina inhibidores de bromodominios Download PDFInfo
- Publication number
- ES2526671T3 ES2526671T3 ES11725769.1T ES11725769T ES2526671T3 ES 2526671 T3 ES2526671 T3 ES 2526671T3 ES 11725769 T ES11725769 T ES 11725769T ES 2526671 T3 ES2526671 T3 ES 2526671T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- ring
- carbocyclyl
- groups
- elements
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Un compuesto de fórmula (I) o una sal del mismo**Fórmula** en la que R1 es alquilo C1-3; R2 es -NR2aR2a' o -OR2b; en los que uno de R2a o R2'a es hidrógeno, y R2b o el otro de R2a o R2'a son seleccionados de alquilo C1-6, haloalquilo C1-6, R2cR2'cN - alquilo C2-6, R2cO-alquilo C2-6, carbociclilo, carbociclilalquilo C1-4, heterociclilo y heterociclilalquilo C1- 4, en los que cualquiera de los grupos carbociclilo o heterociclilo está opcionalmente sustituido con uno o más grupos seleccionados de halógeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, carbonilo, -CO-carbociclilo, azido, amino, hidroxilo y ciano, o dos grupos adyacentes en cualquiera de los grupos carbociclilo o heterociclilo, junto con los átomos de interconexión forman un anillo de 5 ó 6 elementos cuyo anillo puede contener 1 ó 2 heteroátomos seleccionados independientemente de O, S y N; o R2a y R2'a junto con el átomo de N al que están unidos forman un anillo de 5, 6 ó 7 elementos, que puede contener opcionalmente 1 o 2 heteroátomos seleccionados independientemente de O, S y N; en el que el anillo de 5, 6 ó 7 elementos puede estar además opcionalmente sustituido con alquilo C1-6; R2c y R2'c son independientemente hidrógeno o alquilo C1-6; cada R3 es seleccionado independientemente de hidrógeno, hidroxi, halo, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, ciano, CF3, -OCF3, -COOR5, - aquilC1-4 NR6R7 y -aquil C1-4 OH; R4 es un grupo carbocíclico aromático o heterociclilo aromático; en el que el grupo carbociclilo o heterociclilo aromático está opcionalmente sustituido con uno o más grupos seleccionados de halo, alquilo C1-6, alcoxi C1-6 y un grupo aquil C1-4 NR6R7; R5 es alquilo C1-3; en cada aparición, R6 y R7 son independientemente hidrógeno, alquilo C1-6, o C(O) alquilo C1-6, o R6 y R7 junto con el átomo de N al que están unidos forman un anillo de 5, 6 ó 7 elementos que opcionalmente contiene 1 ó 2 heteroátomos adicionales seleccionados independientemente de O, S y N; en el que el anillo de 5, 6 ó 7 elementos puede estar además opcionalmente sustituido con uno o más grupos alquilo C1-6, -C(O) alquilo C1-6, amino o hidroxilo; y n es un entero entre 1 y 5.
Description
E11725769
18-12-2014
Se añadió ácido 4-metoxibencenoborónico (50,5 mg), carbonato de sodio (64,5 mg) y cloruro de bis (trifenilfosfina) paladio (II) (19,4 mg) a un vial de microondas de 2 -5 ml. Se añadió una solución de trifluorometanosulfonato de (4S) -6-(4-clorofenil) -4-[2-(etilamino) -2-oxoetil] -1-metil-4H-[1,2,4] triazolo [4,3-a] [1,4] benzodiazepin-8-ilo (para 5 una preparación véase el Intermedio 3) (150 mg) en DME (3 ml) y agua (1 ml) y la mezcla de reacción se calentó a 120°C durante 20 min (microondas). La mezcla de reacción se repartió entre acetato de etilo (10 ml) y agua (10 ml). La fase orgánica se separó, se lavó con agua (10 ml) y salmuera (10 ml). La fase orgánica se secó y el disolvente se evaporó. El residuo se sometió a cromatografía (metanol al 0% -5%: DCM) para dar 2 -{(4S) -6-(4clorofenil) -1-metil-8-[4-(metiloxi) fenil] -4H [1,2,4] triazolo [4,3-a] [1,4] benzodiazepin-4-il} -N-etilacetamida en
10 forma de un sólido marrón claro (84 mg).
LCMS (formiato): MH+ 500 / 502, TR 1,08 min.
Ejemplo 4: 2 -[(4S) -6-(4-clorofenil) -1-metil-8-(1H-pirazol-5-yi) -4H [1,2,4] triazolo [4,3-a ] [1,4] benzodiacepina 4-il] -N-etilacetamida
15 Se añadió carbonato de sodio (43,0 mg), ácido 1 H-pirazol-5-borónico (24,8 mg) y cloruro de bis (trifenilfosfina) paladio (II) (13,0 mg) a un vial de microondas de 2 -5 ml. Se añadió una solución de trifluorometanosulfonato de (4S) -6-(4-clorofenil) -4-[2-(etilamino) -2-oxoetil] -1-metil-4H-[1,2,4] triazolo [4,3-a] [1,4] benzodiazepin-8-ilo (para una preparación véase el Intermedio 3) (100 mg) en DME (3 ml) y agua (1 ml). La mezcla de reacción se calentó a 120°C durante 30 min (microondas). Se añadió acetato de etilo (2 ml) y la fase acuosa se separó. La fase orgánica
20 se secó y el disolvente se evaporó. El residuo se sometió a cromatografía (metanol al 0% -5%: DCM) y el producto se purificó adicionalmente por MDAP (modificador de formiato). La goma resultante se cargó en una columna SCX-2 de 1 g y se lavó con amoniaco en metanol (2 M) para dar 2-[(4S)-6-(4-clorofenil)-1-metil-8-(1H-pyrazol-5-il)4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-il] -N-etilacetamida en forma un aceite marrón (15,6 mg).
LCMS (formiato): MH+ 460 / 462, TR 0,80 min
27
Claims (1)
-
imagen1 imagen2 imagen3
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201010514 | 2010-06-22 | ||
GBGB1010514.6A GB201010514D0 (en) | 2010-06-22 | 2010-06-22 | Novel compounds |
GB201106801 | 2011-04-21 | ||
GBGB1106801.2A GB201106801D0 (en) | 2011-04-21 | 2011-04-21 | Novel compounds |
PCT/EP2011/060179 WO2011161031A1 (en) | 2010-06-22 | 2011-06-20 | Benzotriazolodiazepine compounds inhibitors of bromodomains |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2526671T3 true ES2526671T3 (es) | 2015-01-14 |
Family
ID=44310320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11725769.1T Active ES2526671T3 (es) | 2010-06-22 | 2011-06-20 | Compuestos de benzotriazoldiazepina inhibidores de bromodominios |
Country Status (5)
Country | Link |
---|---|
US (1) | US9085582B2 (es) |
EP (1) | EP2585465B1 (es) |
JP (1) | JP5844358B2 (es) |
ES (1) | ES2526671T3 (es) |
WO (1) | WO2011161031A1 (es) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
KR101857599B1 (ko) | 2010-05-14 | 2018-05-14 | 다나-파버 캔서 인스티튜트 인크. | 종양형성, 염증성 질환 및 다른 장애를 치료하기 위한 조성물 및 방법 |
US9301962B2 (en) | 2010-05-14 | 2016-04-05 | Baylor College Of Medicine | Male contraceptive compositions and methods of use |
WO2011143660A2 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
EP2705039B1 (en) | 2011-05-04 | 2017-07-26 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
WO2013033269A1 (en) * | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
WO2013033268A2 (en) * | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
JP5992054B2 (ja) | 2011-11-29 | 2016-09-14 | ノバルティス アーゲー | ピラゾロピロリジン化合物 |
WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
TWI602820B (zh) * | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
EP2864336B1 (en) | 2012-06-06 | 2016-11-23 | Constellation Pharmaceuticals, Inc. | Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof |
EP2900672B1 (de) * | 2012-09-28 | 2017-02-22 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 5-aryl-triazolo-azepine |
US9422290B2 (en) * | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
US9266891B2 (en) | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
EP2948453B1 (en) | 2013-01-22 | 2017-08-02 | Novartis AG | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
EP2958922A1 (de) * | 2013-02-22 | 2015-12-30 | Bayer Pharma Aktiengesellschaft | Pyrrolo- und pyrazolo-triazolodiazepine als bet-proteininhibitoren zur behandlung von hyper-proliferativen erkrankungen |
EP2970312B1 (en) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
EP2970262A1 (en) * | 2013-03-11 | 2016-01-20 | AbbVie Inc. | Bromodomain inhibitors |
MX2015012158A (es) | 2013-03-11 | 2015-12-01 | Abbvie Inc | Inhibidores de bomodominio tetraciclicos fusionados. |
UY35395A (es) * | 2013-03-12 | 2014-10-31 | Abbvie Inc | Inhibidores de bromodominios tetracíclicos |
US9714946B2 (en) | 2013-03-14 | 2017-07-25 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
EP3581576B1 (en) | 2013-03-15 | 2022-01-26 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors for use in the treatment of a proliferative disease in combination with a janus kinase inhibitor |
BR112015027130A2 (pt) | 2013-04-26 | 2018-07-24 | Beigene Ltd | 5-(3,5-dimetilisoxazol-4-il)indolin-2-ona substituído |
US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
MX2015016344A (es) | 2013-05-27 | 2016-03-01 | Novartis Ag | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. |
AU2014272700B2 (en) | 2013-05-28 | 2016-12-01 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease |
CA2912986A1 (en) | 2013-05-28 | 2014-12-04 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease |
EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
BR112016001457A2 (pt) * | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
WO2015075665A1 (en) | 2013-11-21 | 2015-05-28 | Novartis Ag | Pyrrolopyrrolone derivatives and their use as bet inhibitors |
WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
GB201320994D0 (en) * | 2013-11-28 | 2014-01-15 | Univ Dundee | Enzyme function probes |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ジアゼパン誘導体の使用 |
JP2017504653A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ジアミノピリミジンベンゼンスルホン誘導体およびその使用 |
US9695172B2 (en) | 2014-01-31 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
US10925881B2 (en) | 2014-02-28 | 2021-02-23 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
CN107074861A (zh) | 2014-02-28 | 2017-08-18 | 密执安大学评议会 | 作为bet溴结构域抑制剂的9h嘧啶并[4,5‑b]吲哚和相关类似物 |
CN106414442B (zh) | 2014-04-23 | 2019-03-15 | 因赛特公司 | 作为BET蛋白抑制剂的1H-吡咯并[2,3-c]吡啶-7(6H)-酮和吡唑并[3,4-c]吡啶-7(6H)-酮 |
ES2725928T3 (es) | 2014-06-20 | 2019-09-30 | Constellation Pharmaceuticals Inc | Formas cristalinas de 2-((4S)-6-(4-clorofenil)-1-metil-4H-benzo[c]isoxazolo[4,5-e]azepin-4-il)acetamida |
WO2016022902A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
CA2955077A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
AU2015339511B2 (en) | 2014-10-27 | 2020-05-14 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
EP3262045A1 (en) | 2015-02-27 | 2018-01-03 | The Regents of The University of Michigan | 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors |
GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
JP6764877B2 (ja) | 2015-03-30 | 2020-10-07 | ジュビラント バイオシス リミテッドJubilant Biosys Limited | がん治療に有用な1−(シクロ)アルキルピリジン−2−オンの三環式縮合誘導体 |
WO2016196065A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Methods and compositions for assessing responsiveness of cancers to bet inhibitors |
EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS |
WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
EP3314005A1 (en) | 2015-06-26 | 2018-05-02 | Tensha Therapeutics, Inc. | Treatment of nut midline carcinoma |
RU2750164C2 (ru) | 2015-09-11 | 2021-06-22 | Дана-Фарбер Кэнсер Инститьют, Инк. | Цианотиенотриазолодиазепины и пути их применения |
KR20180051576A (ko) | 2015-09-11 | 2018-05-16 | 다나-파버 캔서 인스티튜트 인크. | 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도 |
TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
WO2017091673A2 (en) | 2015-11-25 | 2017-06-01 | Dana-Farber Cancer Institute, Inc. | Bivalent bromodomain inhibtors and uses thereof |
ES2882066T3 (es) | 2016-02-15 | 2021-12-01 | Univ Michigan Regents | 1,4-oxazepinas fusionadas y análogos relacionados como inhibidores de bromodominio BET |
RU2743432C2 (ru) | 2016-04-06 | 2021-02-18 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Деструкторы белка mdm2 |
US10759808B2 (en) | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
AU2017250076B2 (en) | 2016-04-12 | 2021-07-22 | The Regents Of The University Of Michigan | Bet protein degraders |
AU2017251537B2 (en) | 2016-04-15 | 2020-10-08 | Abbvie Inc. | Bromodomain inhibitors |
FI3472157T3 (fi) | 2016-06-20 | 2023-06-01 | Incyte Corp | Bet-inhibiittorin kiteisiä kiinteitä muotoja |
WO2018022802A1 (en) | 2016-07-26 | 2018-02-01 | University Of Southern California | Selective bromodomain inhibition of fungal bdf1 |
AU2017326175B2 (en) | 2016-09-13 | 2022-01-27 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as BET protein degraders |
US11466028B2 (en) | 2016-09-13 | 2022-10-11 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines as BET protein degraders |
EP3577120A1 (en) | 2017-02-03 | 2019-12-11 | The Regents of The University of Michigan | Fused 1,4-diazepines as bet bromodomain inhibitors |
WO2019055444A1 (en) | 2017-09-13 | 2019-03-21 | The Regents Of The University Of Michigan | DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS |
CN107759607B (zh) * | 2017-11-29 | 2019-08-23 | 上海万巷制药有限公司 | 具有抗肿瘤活性的三氮唑并二氮卓化合物及其制备方法 |
EP3828183A4 (en) | 2018-07-25 | 2022-03-09 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | SULFOXIMINE COMPOUND AS BROMO-DOMAIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF |
WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
TW202219056A (zh) | 2020-06-23 | 2022-05-16 | 美商建南德克公司 | 巨環化合物及其使用方法 |
UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
WO2023205251A1 (en) | 2022-04-19 | 2023-10-26 | Nuevolution A/S | Compounds active towards bromodomains |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3610848A1 (de) | 1986-04-01 | 1987-10-15 | Boehringer Ingelheim Kg | Neue 1,4-diazepine |
MC1999A1 (fr) * | 1987-12-18 | 1990-01-26 | Hoffmann La Roche | Composes tricycliques |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
EP0638560A4 (en) | 1991-10-11 | 1995-03-29 | Yoshitomi Pharmaceutical | MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *. |
JPH06128257A (ja) | 1992-10-13 | 1994-05-10 | Yoshitomi Pharmaceut Ind Ltd | ピリドジアゼピン化合物 |
CA2176020A1 (en) | 1993-11-22 | 1995-06-01 | John J. Baldwin | Benzodiazepines |
AU694278B2 (en) | 1994-11-18 | 1998-07-16 | Japan Tobacco Inc. | Osteoporosis remedy and triazepine compound |
CN1227555A (zh) | 1996-06-12 | 1999-09-01 | 日本烟草产业株式会社 | 细胞因子生成抑制剂、三氮䓬化合物及其中间体 |
DK0989131T3 (da) | 1996-09-13 | 2003-03-03 | Mitsubishi Pharma Corp | Thienotriazolodiazepinforbindelser og deres medicinske anvendelse |
WO2005044354A1 (en) | 2003-11-03 | 2005-05-19 | Glaxo Group Limited | A fluid dispensing device |
US7223733B2 (en) | 2004-03-31 | 2007-05-29 | National University Of Singapore | Modulation of TRIP-Br function and method of treating proliferative disorders |
GB0420970D0 (en) | 2004-09-21 | 2004-10-20 | Smithkline Beecham Corp | Novel triazoloquinoline compounds |
AU2006276998A1 (en) * | 2005-05-16 | 2007-02-15 | Wisys Technology Foundation, Inc. | Gabaergic agents to treat memory deficits |
TWI447120B (zh) | 2005-05-30 | 2014-08-01 | Mitsubishi Tanabe Pharma Corp | 噻吩并三唑并苯二氮呯化合物、其醫藥上之用途 |
CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Brd2ブロモドメイン結合剤 |
EP2239264A4 (en) | 2007-12-28 | 2012-01-11 | Mitsubishi Tanabe Pharma Corp | ANTITUMOR AGENT |
GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
-
2011
- 2011-06-20 EP EP11725769.1A patent/EP2585465B1/en not_active Not-in-force
- 2011-06-20 WO PCT/EP2011/060179 patent/WO2011161031A1/en active Application Filing
- 2011-06-20 JP JP2013515827A patent/JP5844358B2/ja not_active Expired - Fee Related
- 2011-06-20 US US13/702,177 patent/US9085582B2/en not_active Expired - Fee Related
- 2011-06-20 ES ES11725769.1T patent/ES2526671T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
JP5844358B2 (ja) | 2016-01-13 |
WO2011161031A1 (en) | 2011-12-29 |
JP2013529611A (ja) | 2013-07-22 |
EP2585465A1 (en) | 2013-05-01 |
US9085582B2 (en) | 2015-07-21 |
US20130079335A1 (en) | 2013-03-28 |
EP2585465B1 (en) | 2014-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2526671T3 (es) | Compuestos de benzotriazoldiazepina inhibidores de bromodominios | |
ES2586908T3 (es) | Derivados de azetidina N-sustituidos | |
ES2640049T3 (es) | Derivados de 3,6-dihidropirimidina 2,4,5,6-sustituidos como inhibidores de la polimerasa del virus de la hepatitis B (VHB) para el tratamiento de, por ejemplo, la hepatitis crónica | |
ES2688600T3 (es) | Procesos para preparar derivados de dihidropirimidina e intermedios de los mismos | |
ES2627911T3 (es) | Derivados de N-[2-fluoro-3-(4-amino-7H-pirrolo[2,3-d]pirimidin-5-carbonil)-fenil]-4-bencenosulfonamida como moduladores de la proteína quinasa Raf para el tratamiento del cáncer | |
UY25204A1 (es) | Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos | |
ES2764223T3 (es) | Procedimiento de producción de un derivado de espirooxindol | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR063142A1 (es) | Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen. | |
AR047678A1 (es) | Derivados de benzamidas y su uso como activadores de glucoquinasa | |
ES2404411T3 (es) | Procedimiento de fabricación de derivados de ácido neuramínico | |
AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
CO6160296A2 (es) | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol | |
CY1115643T1 (el) | Διεγερτης νευρογενεσης ή θεραπευτικος παραγων νευροπαθειας που περιλαμβανει παραγωγα αλκυλ αιθερα ή αλας αυτου | |
AR057408A1 (es) | Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento | |
BRPI0717092B1 (pt) | Processo para preparar azoxistrobina e seu derivado dimetóxi acetal | |
AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
BR0313078A (pt) | Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou de um sal deste farmaceuticamente aceitável | |
ES2656110T3 (es) | Procedimiento sintético para la preparación de 1,2-Bencisotiazolin-3-ona | |
AR073498A1 (es) | Derivados de tieno [2-3-d] pirimidin | |
AR047544A1 (es) | Proceso para la preparacion de compuestos de triazol sustituidos | |
AR042067A1 (es) | Derivados de anilinopirazol utiles en el tratamiento de la diabetes | |
ES2711095T3 (es) | Nueva síntesis quiral de N-acil-(3-sustituida)-(8-sustituida)-5,6-dihidro-[1,2,4]triazolo [4,3-a] pirazinas | |
TW200727077A (en) | Photoresist composition | |
BR112019017667A2 (pt) | Fotoiniciador, e, método de síntese dos fotoiniciadores. |